<div id="readability-page-1"><p>Caxton Associates LLP bought a new stake in  Arvinas, Inc. (NASDAQ:ARVN - Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 298,062 shares of the company's stock, valued at approximately $2,194,000. Caxton Associates LLP owned 0.41% of Arvinas at the end of the most recent reporting period.</p><ul><li> 3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023</li></ul><p>A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in  Arvinas by 18.4% in the first quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company's stock valued at $58,703,000 after acquiring an additional 1,299,639 shares during the period.  Deutsche Bank AG lifted its holdings in shares of  Arvinas by 5.3% in the 1st quarter. Deutsche Bank AG now owns 228,633 shares of the company's stock worth $1,605,000 after purchasing an additional 11,413 shares in the last quarter.  Invesco Ltd. grew its position in  Arvinas by 119.4% in the 1st quarter. Invesco Ltd. now owns 81,747 shares of the company's stock valued at $574,000 after purchasing an additional 44,493 shares during the period.  Nuveen LLC acquired a new stake in  Arvinas in the 1st quarter valued at $1,170,000.  Finally, Russell Investments Group Ltd. increased its stake in  Arvinas by 444.8% during the 1st quarter. Russell Investments Group Ltd. now owns 41,549 shares of the company's stock valued at $292,000 after purchasing an additional 33,922 shares in the last quarter. 95.19% of the stock is owned by institutional investors. </p><h2>Insider Activity at Arvinas</h2><p>In related news, Director Briggs Morrison purchased 30,000 shares of the business's stock in a transaction that occurred on Monday, September 22nd. The shares were bought at an average cost of $7.57 per share, with a total value of $227,100.00. Following the acquisition, the director owned 76,021 shares of the company's stock, valued at $575,478.97. This represents a 65.19% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.73% of the stock is owned by insiders. </p><h2>Analyst Upgrades and Downgrades</h2><p>ARVN has been the subject of a number of analyst reports. The Goldman Sachs Group  reiterated a &#34;sell&#34; rating and set a $6.00 price objective (down from $8.00) on shares of Arvinas in a report on Wednesday, October 15th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Arvinas in a research report on Tuesday, December 9th. Wells Fargo &amp; Company decreased their price objective on Arvinas from $16.00 to $15.00 and set an &#34;overweight&#34; rating for the company in a report on Thursday, November 6th. Barclays increased their price objective on Arvinas from $15.00 to $16.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, November 6th. Finally, Bank of America cut Arvinas from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and set a $10.00 target price on the stock. in a research report on Wednesday, September 24th. Eleven analysts have rated the stock with a Buy rating, ten have issued  a Hold rating and two have issued  a Sell rating to the company's stock. According to data from MarketBeat, Arvinas presently has an average rating of &#34;Hold&#34; and a consensus target price of $16.39.</p><p><b>Check Out Our Latest Research Report on ARVN</b></p><h2>Arvinas Stock Up 0.1%</h2><p>Shares of NASDAQ ARVN opened at $12.58 on Monday. The company has a market capitalization of $807.89 million, a PE ratio of -15.53 and a beta of 2.44. The stock's 50 day moving average price is $10.80 and its 200-day moving average price is $8.74. Arvinas, Inc. has a twelve month low of $5.90 and a twelve month high of $21.00. </p><p>Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.48) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.27. Arvinas had a negative return on equity of 9.77% and a negative net margin of 18.73%.The company had revenue of $41.90 million during the quarter, compared to the consensus estimate of $29.36 million. During the same period last year, the business posted ($0.68) earnings per share. Arvinas's revenue was down 59.1% on a year-over-year basis.  As a group, research analysts expect that  Arvinas, Inc. will post -3.81 EPS for the current fiscal year. </p><p>Arvinas announced that its Board of Directors has approved a stock repurchase program on Wednesday, September 17th that authorizes the company to repurchase $100.00 million in  outstanding  shares. This repurchase authorization authorizes the company to reacquire up to 17.9% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's board believes its stock is undervalued. </p><h2>Arvinas Company Profile</h2> (Free Report)<p>Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Arvinas</li><li>Want to Profit on the Downtrend? Downtrends, Explained.</li><li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li><li>Stock Market Sectors: What Are They and How Many Are There? </li><li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li><li>What is a Bond Market Holiday? How to Invest and Trade</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li></ul><p><strong>Want to see what other hedge funds are holding ARVN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arvinas, Inc. (NASDAQ:ARVN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJWTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJWTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Arvinas Right Now?</h2><p>Before you consider Arvinas, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.</p><p>While Arvinas currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARVN

<p>Caxton Associates LLP acquired 298,062 shares of Arvinas, Inc., valued at $2.19 million, owning 0.41% of the company. Other institutional investors also adjusted their stakes. Analysts have mixed ratings on Arvinas, with a consensus target price of $16.39. Arvinas reported better-than-expected quarterly earnings, with revenue down 59.1% year-over-year. The company announced a stock repurchase program.</p>

Caxton Associates LLP Takes $2.19 Million Position in Arvinas, Inc. $ARVN